Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

1 Mar 2012

Abstract excerpt

BACKGROUND: Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. It is well known that CML cells are genetically unstable. However, the mechanisms by which these cells acquire genetic alterations are poorly understood. Imatinib mesylate is the standard therapy for newly diagnosed CML patients. Imatinib mesylate targets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Kruppel-like factors research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22388797
DOI: 10.1097/fpc.0b013e328351f3e9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progressionPMID 22388797Read ↗

Molecular and cellular bases of chronic myeloid leukemiaSemantic proximity Read ↗

The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib TherapySemantic proximity Read ↗

The development of imatinib as a therapeutic agent for chronic myeloid leukemiaSemantic proximity Read ↗

A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic DrugsSemantic proximity Read ↗

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read ↗

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic optionsSemantic proximity Read ↗

Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.Semantic proximity Read ↗

Therapeutic targets in chronic myeloid leukaemiaSemantic proximity Read ↗

The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)Semantic proximity Read ↗

Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid LeukemiaSemantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.